Latest on Ultrasound Renal Denervation

Published: 22 June 2022

  • Views:

    Views Icon 4003
  • Likes:

    Heart Icon 7
  • episode_image
    Part 3 | Session 1 ACC 2022 Symposium
    Michael Weber, Felix Mahfoud, Ajay J Kirtane, Michael Bloch
  • episode_image
    Part 3 | Session 2 TCT 2021 Symposium
    Chandan Devireddy, Ajay J Kirtane, Felix Mahfoud, Naomi Fisher

Overview

Ultrasound Renal Denervation (uRDN) is an innovative therapy option for the treatment of uncontrolled hypertension. uRDN therapy is delivered in a minimally invasive procedure that may lower high blood pressure by treating overactive renal nerves with ultrasound energy.

 

This page provides an overview of uRDN technology and the latest evidence from its associated RADIANCE clinical program.

 

The PARADISETM System is Limited to Investigational Use Only in the United States. Approved for distribution in CE mark countries only.
This educational content is supported by:

What you will learn:

  • How uRDN works and its potential benefits for patients suffering from uncontrolled hypertension
  • The clinical evidence supporting uRDN and its implications for the field of hypertension
  • The process for building a uRDN centre and therapy network

This page is designed for:

  • Interventional cardiologists
  • General cardiologists
  • Hypertension specialists
  • Nephrologists
  • Interventional radiologists

More from this programme

Part 3

Discussion With Experts

Part 5

Patient Perspective & Provider Referral Development

Understand patient preference and referral development

Part 6

RADIANCE II Pivotal Trial for Paradise Ultrasound Renal Denervation System in Patients With Hypertension

Faculty Biographies

Felix Mahfoud

Felix Mahfoud

Associate Professor and Senior Physician

Professor Felix Mahfoud is an Associate Professor and senior physician of Internal Medicine and Cardiology at Saarland University Hospital, and Affiliate/Visiting Professor Harvard-MIT Biomedical Engineering, Institute of Medical Engineering and Science, Cambridge, US. Professor Mahfoud completed training in Cardiology and Interventional Cardiology at the Department for Internal Medicine III, Saarland University Hospital, Germany in 2014. Since 2017, he has served as Vice Chairman of the ‘Working Group on Interventional Hypertension Treatment’ for the European Society of Hypertension, and as a Committee Member of the 2018 Hypertension Guidelines.

View full profile